Talking Medicines creates AI tool for patient experiences
Drug-GPT, which is available on Talking Medicine’s PatientMetRx 2.0 platform, uses curated social data to help uncover patient insights to inform healthcare advertising.
In addition, Drug-GPT provides natural language responses and summaries, with subscribers able to answer questions on how patients experience medication and treatments compared with the views of healthcare professionals.
The company licenses the GPT models from Microsoft to make sure of a closed ecosystem around Drug-GPT using its own curated social data of patients and healthcare practitioners.
The PatientMetRx 2.0 platform has also added other new features, such as a natural language search function and more ability to gauge the views of healthcare professionals.
Jo Halliday, chief executive and co-founder at Talking Medicines, said: “We are really excited by the potential of Drug-GPT to transform the way that healthcare advertising agencies analyse insights on complex patient and healthcare professional social data.”
We hope you enjoyed this article.
Research Live is published by MRS.
The Market Research Society (MRS) exists to promote and protect the research sector, showcasing how research delivers impact for businesses and government.
Members of MRS enjoy many benefits including tailoured policy guidance, discounts on training and conferences, and access to member-only content.
For example, there's an archive of winning case studies from over a decade of MRS Awards.
Find out more about the benefits of joining MRS here.
0 Comments